{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gonorrhoea/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"caa85d19-223f-5ca5-ae12-313a1b2462d1","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field 091031a5-232a-49a3-854a-0d74767eb674 --><h2>Azithromycin</h2><!-- end field 091031a5-232a-49a3-854a-0d74767eb674 -->","summary":"","htmlStringContent":"<!-- begin item a1c46898-b8b5-47b3-92eb-a0404b29a92c --><!-- end item a1c46898-b8b5-47b3-92eb-a0404b29a92c -->","topic":{"id":"8aeba2d1-9f1a-5428-a119-41fa94223706","topicId":"4b4cdbb6-97a0-4b13-a04c-d857b72bcddf","topicName":"Gonorrhoea","slug":"gonorrhoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"803822d1-16b6-5c36-b47d-9a6e8e236c06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b8d98590-b989-554f-8ccb-804279dab0d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4ac6e3b9-f31e-5367-b177-171c1cd87bd7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"41812e79-dbe3-5991-8344-05de91dff192","slug":"changes","fullItemName":"Changes"},{"id":"bbabf43d-27dd-5795-b02b-9891c7e9e7ca","slug":"update","fullItemName":"Update"}]},{"id":"cd231f06-b527-5de3-a8cb-277fd6f84587","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"858e0da7-8025-510b-ac87-1055c9b510e0","slug":"goals","fullItemName":"Goals"},{"id":"b9efda8e-7814-5479-af6b-1272844f3546","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"874bc02c-2022-584f-bc91-b99489f3ac6c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"17fcc032-43d9-5c38-b19b-e10bef0648f1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1033f77b-d5e5-5700-b7f9-f314bb1daef3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"11e8f7de-1c3f-5692-a9e4-f2c1645e1023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f889ee27-2135-5f9e-b131-fb46452febe4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"55283c6e-a75b-5deb-8827-406245e897ff","slug":"definition","fullItemName":"Definition"},{"id":"cf7e0416-d49c-57de-8063-ebf536922bcc","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6c929d32-5621-5a53-9e9b-63a3e1523e20","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1196a066-1188-5938-b1d3-932dd0ffc403","slug":"complications","fullItemName":"Complications"}]},{"id":"acc7ed62-ebd4-506d-a105-4b05f6f7e38a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a9a1ae79-f8a2-59e3-a720-8207d27eee47","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee9cef7-bd86-583b-9d57-f5d8f9a5d6d0","slug":"signs-symptoms-in-a-man","fullItemName":"Signs and symptoms in a man"},{"id":"9b460f20-3213-5956-896f-ccc5156c9d32","slug":"signs-symptoms-in-a-woman","fullItemName":"Signs and symptoms in a woman"},{"id":"e568c796-6f9e-5513-a973-7efca33d5b62","slug":"confirmation-of-diagnosis","fullItemName":"Confirmation of diagnosis"},{"id":"44933641-db44-5935-9459-ea8e78869d57","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"e0f6f6d2-d4a8-5801-b817-0588e8540a04","slug":"possible-sexual-abuse","fullItemName":"Possible sexual abuse"}]},{"id":"d05b0423-47bb-53df-ab5a-8730ca4d3325","fullItemName":"Management","slug":"management","subChapters":[{"id":"171cfead-d784-5eab-b668-c3fe9015a93a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"98eac615-b29a-5de3-a795-37b42615eb61","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c11c59e-3407-52b9-a870-aed88dcd9236","slug":"cephalosporins-ceftriaxone-or-cefixime","fullItemName":"Cephalosporins (ceftriaxone or cefixime)"},{"id":"af56affe-2e43-5ee7-b94a-333ead3b8efa","slug":"quinolones-ciprofloxacin-or-ofloxacin","fullItemName":"Quinolones (ciprofloxacin or ofloxacin)"},{"id":"caa85d19-223f-5ca5-ae12-313a1b2462d1","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39f7e7ee-870b-55c8-9cd9-55320d487f24","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"05886abb-50fd-51e9-b3c2-e2e99ad9b241","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bdd6db63-13f7-5183-a3a2-63b619818fb3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d44a69c-3824-5509-a756-cda3bc1bd50a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e5526ef2-c93a-595d-a0c1-8068bad91f10","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0092236d-21ec-5777-85c0-6e95f9962a15","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8791b380-0e55-5489-987e-5db590030323","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc36d12c-c9a8-5970-8b4b-74304413a1f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"98eac615-b29a-5de3-a795-37b42615eb61","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"68824f9c-d463-546e-86d8-89177f431e60","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 237e63a3-15ab-49f3-9b4c-a777008452c2 --><h3>Adverse effects</h3><!-- end field 237e63a3-15ab-49f3-9b4c-a777008452c2 -->","summary":"","htmlStringContent":"<!-- begin item 2c9e0e78-3aaf-4330-86d8-a777008450e0 --><!-- begin field ca920440-fd32-48ab-8ccf-a777008452c2 --><ul><li><strong>Possible adverse effects of azithromycin include: </strong><ul><li><strong>Gastrointestinal</strong> — diarrhoea, abdominal pain, nausea, and flatulence (very common). These are the most common adverse effects of all the macrolides, but are milder and less frequent with azithromycin than with erythromycin.</li><li><strong>Infections </strong>— pseudomembranous colitis. Consider this if a person develops severe diarrhoea during, or after treatment with azithromycin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hypersensitivity </strong>— anaphylaxis (rare). </li><li><strong>Hepatotoxicity </strong>—<strong> </strong>including cholestatic jaundice and rash (frequency unknown).</li><li><strong>Skin</strong> <strong>and subcutaneous tissue </strong>— pruritus and rash (common). </li><li><strong>Other adverse effects reported rarely, or very rarely, include:</strong> <ul><li>Pancreatitis. </li><li>QT interval prolongation.</li><li>Arrhythmias.</li><li>Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li><li>Drug reaction with eosinophilia and systemic symptoms (DRESS).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]</p><!-- end field ca920440-fd32-48ab-8ccf-a777008452c2 --><!-- end item 2c9e0e78-3aaf-4330-86d8-a777008450e0 -->","subChapters":[]},{"id":"d6199c3d-42a4-5801-a087-77591ee883ec","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ba349b30-9ffc-4c73-ab5f-a7770084391c --><h3>Contraindications and cautions</h3><!-- end field ba349b30-9ffc-4c73-ab5f-a7770084391c -->","summary":"","htmlStringContent":"<!-- begin item 89553472-4b34-4af6-ae37-a777008435f8 --><!-- begin field d0fbea33-4232-43b0-8c8a-a7770084391c --><ul><li><strong>Do not prescribe azithromycin to people:</strong><ul><li>With severe hepatic impairment.</li></ul></li><li><strong>Prescribe azithromycin with caution to people:</strong><ul><li>Who may be predisposed to prolongation of the QT interval. For example people:<ul><li>With congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency, including Torsades de pointes.</li></ul></li><li>With mild to moderate hepatic impairment.</li><li>With moderate to severe renal impairment.</li><li>With myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]</p><!-- end field d0fbea33-4232-43b0-8c8a-a7770084391c --><!-- end item 89553472-4b34-4af6-ae37-a777008435f8 -->","subChapters":[]},{"id":"d5bc1770-0335-58dd-b4d5-1d46096489ab","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 278f2fe8-390d-4f65-973c-a77700846a6f --><h3>Drug interactions</h3><!-- end field 278f2fe8-390d-4f65-973c-a77700846a6f -->","summary":"","htmlStringContent":"<!-- begin item 00830ecb-f7fd-41ac-90b5-a777008467cd --><!-- begin field 6721a3e7-a9e8-4595-b0a6-a77700846a6f --><ul><li><strong>Drug interactions may occur with:</strong><ul><li><strong>Antacids</strong> — plasma concentrations of azithromycin may be reduced. Simultaneous administration should be avoided — azithromycin should be taken at least 2 hours before, or 1 hour after antacids.</li><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— there is a possible increased risk of myopathy.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Ciclosporin </strong>— azithromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, terfenadine, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-<sub>2</sub> agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Colchicine </strong>— concomitant administration has been reported to increase levels of P-glycoprotein substrate. This protein has been linked to barriers to successful chemotherapy treatment in cancer.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]</p><!-- end field 6721a3e7-a9e8-4595-b0a6-a77700846a6f --><!-- end item 00830ecb-f7fd-41ac-90b5-a777008467cd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}